{
    "2018-04-16": [
        [
            {
                "time": "2018-01-03",
                "original_text": "How AbbVie’s Humira Performed in 4Q17 and 2017",
                "features": {
                    "keywords": [
                        "Humira",
                        "AbbVie",
                        "4Q17",
                        "performance"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Upadacitinib Could Drive AbbVie’s Long-Term Growth",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "AbbVie",
                        "long-term growth"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "How AbbVie Performed in 4Q17 and Fiscal 2017",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "4Q17",
                        "fiscal 2017",
                        "performance"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Vanguard S&P 500 ETF Experiences Big Outflow",
                "features": {
                    "keywords": [
                        "Vanguard",
                        "S&P 500 ETF",
                        "outflow"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "ETFs"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Consolidated Research: 2018 Summary Expectations for Amazon, Rayonier, The Boeing, Sanchez Energy, AbbVie, and American Airlines Group — Fundamental Analysis, Key Performance Indications",
                "features": {
                    "keywords": [
                        "Amazon",
                        "Rayonier",
                        "Boeing",
                        "Sanchez Energy",
                        "AbbVie",
                        "American Airlines Group",
                        "fundamental analysis",
                        "key performance indications"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "real estate",
                        "aerospace",
                        "energy",
                        "pharmaceuticals",
                        "airlines"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Johnson & Johnson’s Revenue Estimates for 1Q18",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "revenue estimates",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}